Showing 1 - 10 results of 10 for search 'Kiyotaka Yoh', query time: 0.04s
Refine Results
-
1
Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis o... by Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh
Published 2025-01-01
Article -
2
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study by Mototsugu Shimokawa, Kaname Nosaki, Takashi Seto, Kadoaki Ohashi, Masahiro Morise, Hidehito Horinouchi, Jun Sakakibara, Haruyasu Murakami, Seiji Yano, Miyako Satouchi, Shingo Matsumoto, Koichi Goto, Kiyotaka Yoh
Published 2020-03-01
Article -
3
Identification of biological properties of intralymphatic tumor related to the development of lymph node metastasis in lung adenocarcinoma. by Keisuke Kirita, Genichiro Ishii, Rie Matsuwaki, Yuki Matsumura, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Koichi Goto, Hironobu Ohmatsu, Yuichiro Ohe, Kanji Nagai, Atsushi Ochiai
Published 2013-01-01
Article -
4
PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study by Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
Published 2024-04-01
Article -
5
Impact of concomitant medication on clinical outcomes in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study by Kaho Miura, Yoshiyuki Sano, Seiji Niho, Kenji Kawasumi, Nobuo Mochizuki, Kiyotaka Yoh, Shingo Matsumoto, Yoshitaka Zenke, Takaya Ikeda, Kaname Nosaki, Keisuke Kirita, Hibiki Udagawa, Koichi Goto, Toshikatsu Kawasaki, Kazuhiko Hanada
Published 2021-07-01
Article -
6
A secondary RET mutation in the activation loop conferring resistance to vandetanib by Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Niho, Rakhee Chauhan, Phillip P. Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki, Genichiro Ishii, Hitoshi Ichikawa, Satoru Nagatoishi, Kouhei Tsumoto, Yasushi Okuno, Kiyotaka Yoh, Neil Q. McDonald, Koichi Goto
Published 2018-02-01
Article -
7
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion by Shunta Mori, Hiroki Izumi, Mitsugu Araki, Jie Liu, Yu Tanaka, Yosuke Kagawa, Yukari Sagae, Biao Ma, Yuta Isaka, Yoko Sasakura, Shogo Kumagai, Yuta Sakae, Kosuke Tanaka, Yuji Shibata, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Yasushi Okuno, Koichi Goto, Susumu S. Kobayashi
Published 2024-04-01
Article -
8
Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immuno... by Takehito Shukuya, MD, PhD, Kazuya Takamochi, MD, PhD, Hiroyuki Sakurai, MD, PhD, Kiyotaka Yoh, MD, Tomoyuki Hishida, MD, PhD, Masahiro Tsuboi, MD, PhD, Yasushi Goto, MD, PhD, Yujin Kudo, MD, PhD, Yasuhisa Ohde, MD, PhD, Sakae Okumura, MD, Masataka Taguri, PhD, Hideo Kunitoh, MD
Published 2022-05-01
Article -
9
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) by Kageaki Watanabe, MD, Yukio Hosomi, MD, PhD, Katsuhiko Naoki, MD, PhD, Yoshiro Nakahara, MD, PhD, Yoko Tsukita, MD, PhD, Hirotaka Matsumoto, MD, PhD, Kiyotaka Yoh, MD, Yasuhito Fujisaka, MD, PhD, Satoshi Takahashi, MD, PhD, Saori Takata, MD, PhD, Kazuhiro Usui, MD, PhD, Kazuma Kishi, MD, PhD, Go Naka, MD, PhD, Shu Tamano, MSS, Kohei Uemura, PhD, Hideo Kunitoh, MD, PhD
Published 2024-11-01
Article -
10
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma by Yuji Uehara, MD, Hiroki Izumi, MD, PhD, Tetsuro Taki, MD, PhD, Tetsuya Sakai, MD, PhD, Hibiki Udagawa, MD, PhD, Eri Sugiyama, MD, PhD, Shigeki Umemura, MD, PhD, Yoshitaka Zenke, MD, PhD, Shingo Matsumoto, MD, PhD, Kiyotaka Yoh, MD, PhD, Shoko Kubota, MD, PhD, Keiju Aokage, MD, PhD, Naoya Sakamoto, MD, PhD, Shingo Sakashita, MD, PhD, Motohiro Kojima, MD, PhD, Michiko Nagamine, MD, PhD, Yukio Hosomi, MD, PhD, Masahiro Tsuboi, MD, PhD, Koichi Goto, MD, PhD, Genichiro Ishii, MD, PhD
Published 2025-03-01
Article